Galectin Therapeutics Return on Equity

Galectin Therapeutics (GALT) currently reports a ROE of 20.35%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Galectin Therapeutics's ROE history and peer comparisons.

Galectin Therapeutics's ROE of 20.35% is lower than the Healthcare sector average of 22.01%. That is roughly 7.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Galectin Therapeutics's current 20.35% should be judged against Healthcare norms (sector average: 22.01%) and against GALT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 20.35%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Galectin Therapeutics, and consider following GALT for alerts when major investors trade the stock.

Galectin Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 20.35% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GALT with unrelated industries.